← All stocks

PRECISION BIOSCIENCES INC

DTIL Net buying
CIK 0001357874 #3786 in the set updated 18 Sep 2026
Bought (120 mo)
$2.12M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$5.59M
$922.34K on a plan · $4.14M straight out of an exercise
Sold at will
$523.94K
15 of 80 sales
Net
−$3.47M
+$1.60M against sales at will

By person

21 insiders · 119 transactions
1.4×

Michael Amoroso holds only 1.4 times base salary in stock. $934.63K of shares against $650.88K in salary for 2025.

Salary from the company's own proxy. The shares are what Michael Amoroso last reported holding, valued at $3.84, the price Common Stock was last bought or sold at on the open market here, on 18 Feb 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
JANTZ DEREK
Chief Scientific Officer
$1.62M (17) scheduled
−$1.62M
4,055,174
$15.57M
+5.5%
KANE MATTHEW R.
President and CEO
$1.61M (15) scheduled
−$1.61M
2,024,438
$7.77M
+11.0%
THOMSON DAVID S.
Chief Operating Officer
$1.24M (7) scheduled
−$1.24M
111,513
$428.21K
+2,434%
FMR LLC entity
See Remark 1
$800.00K (1)
+$800.00K
3,738,248
$14.35M
venBio Global Strategic Fund, L.P. entity
Director
$800.00K (1)
+$800.00K
4,265,141
$16.38M
Amoroso Michael
President and CEO
$616.53K (11) scheduled
−$616.53K
243,392
$934.63K
Scimeca Dario
General Counsel and Secretary
$169.10K (13) scheduled
−$169.10K
56,457
$216.79K
SMITH J. JEFFERSON
Chief Research Officer
$122.59K (7) scheduled
−$122.59K
121,926
$468.20K
YAO TONY DUNG LING
Director
$100.03K (1)
+$100.03K
166,903
$640.91K
Buehler Kevin
Director
$63.32K (3)
+$63.32K
49,137
$188.69K
Germano Geno J
Director
$47.57K (3)
+$47.57K
44,883
$172.35K
List Alan
Chief Medical Officer
$45.73K (6)
−$45.73K
4,488
$17.23K
Kelly John Alexander
Chief Financial Officer
$209.27K (7)
$164.22K (4) scheduled
+$45.05K
125,883
$483.39K
Brown Melinda
Director
$43.13K (5)
+$43.13K
44,346
$170.29K
Heery Christopher
Chief Medical Officer
$30.02K (2)
+$30.02K
2,485
$9.54K
Frankel Stanley
Director
$26.11K (2)
+$26.11K
40,478
$155.44K
+80,856%
ANSARI ABID
Chief Financial Officer
144,401
$554.50K
+6,737%
Schinazi Raymond F
Director
93,048
$357.30K
Pire Shari Lisa
Director
35,028
$134.51K
Barton Shane
VP & Corporate Controller
27,502
$105.61K
Wadsworth Samuel C.
Director
4,202
$16.14K

No percentages here. This company's share count has moved by a factor of 3.6 over the window, from 7,671,059 to 27,601,554 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
SMITH J. JEFFERSON
21 Jan 2026
Chief Research Officer
Sold after exercise
10,200
$4.03
$41.11K
Amoroso Michael
3 Nov 2025
President and CEO
Sold after exercise
3,409
$6.49
$22.12K
THOMSON DAVID S.
23 Jun 2021
Chief Operating Officer
Sold after exercise
30,000
$10.65
$319.50K
THOMSON DAVID S.
21 Jun 2021
Chief Operating Officer
Sold after exercise
15,000
$10.77
$161.55K
THOMSON DAVID S.
18 Jun 2021
Chief Operating Officer
Sold after exercise
10,000
$11.00
$110.00K
THOMSON DAVID S.
17 Jun 2021
Chief Operating Officer
Sold after exercise
10,000
$10.44
$104.40K
THOMSON DAVID S.
15 Jun 2021
Chief Operating Officer
Sold after exercise
2,858
$11.20
$32.01K
THOMSON DAVID S.
11 Jun 2021
Chief Operating Officer
Sold after exercise
30,000
$11.52
$345.60K
JANTZ DEREK
14 May 2021
Chief Scientific Officer
Sold after exercise
9,673
$9.17
$88.70K
JANTZ DEREK
13 May 2021
Chief Scientific Officer
Sold after exercise
9,673
$9.15
$88.51K
KANE MATTHEW R.
13 May 2021
President and CEO
Sold after exercise
9,675
$8.96
$86.69K
JANTZ DEREK
12 May 2021
Chief Scientific Officer
Sold after exercise
9,676
$8.72
$84.37K
KANE MATTHEW R.
10 May 2021
President and CEO
Sold after exercise
9,746
$8.25
$80.40K
KANE MATTHEW R.
7 May 2021
President and CEO
Sold after exercise
9,742
$8.57
$83.49K
JANTZ DEREK
19 Apr 2021
Chief Scientific Officer
Sold after exercise
9,676
$8.69
$84.08K
JANTZ DEREK
16 Apr 2021
Chief Scientific Officer
Sold after exercise
9,675
$8.84
$85.53K
JANTZ DEREK
15 Apr 2021
Chief Scientific Officer
Sold after exercise
9,676
$8.76
$84.76K
KANE MATTHEW R.
12 Apr 2021
President and CEO
Sold after exercise
9,741
$8.67
$84.45K
KANE MATTHEW R.
9 Apr 2021
President and CEO
Sold after exercise
9,737
$8.87
$86.37K
KANE MATTHEW R.
8 Apr 2021
President and CEO
Sold after exercise
9,736
$9.00
$87.62K
JANTZ DEREK
18 Mar 2021
Chief Scientific Officer
Sold after exercise
9,665
$11.08
$107.09K
JANTZ DEREK
17 Mar 2021
Chief Scientific Officer
Sold after exercise
9,665
$10.92
$105.54K
JANTZ DEREK
16 Mar 2021
Chief Scientific Officer
Sold after exercise
9,661
$11.97
$115.64K
KANE MATTHEW R.
12 Mar 2021
President and CEO
Sold after exercise
9,712
$11.36
$110.33K
KANE MATTHEW R.
11 Mar 2021
President and CEO
Sold after exercise
9,711
$11.38
$110.51K
KANE MATTHEW R.
10 Mar 2021
President and CEO
Sold after exercise
9,710
$11.79
$114.48K
JANTZ DEREK
22 Feb 2021
Chief Scientific Officer
Sold after exercise
9,660
$12.04
$116.31K
JANTZ DEREK
19 Feb 2021
Chief Scientific Officer
Sold after exercise
9,663
$11.55
$111.61K
KANE MATTHEW R.
18 Feb 2021
President and CEO
Sold after exercise
9,705
$12.23
$118.69K
JANTZ DEREK
18 Feb 2021
Chief Scientific Officer
Sold after exercise
6,871
$12.20
$83.83K
KANE MATTHEW R.
17 Feb 2021
President and CEO
Sold after exercise
9,705
$12.28
$119.18K
KANE MATTHEW R.
16 Feb 2021
President and CEO
Sold after exercise
9,697
$13.30
$128.97K
JANTZ DEREK
29 Jan 2021
Chief Scientific Officer
Sold after exercise
6,444
$12.25
$78.94K
JANTZ DEREK
28 Jan 2021
Chief Scientific Officer
Sold after exercise
6,444
$11.97
$77.13K
JANTZ DEREK
27 Jan 2021
Chief Scientific Officer
Sold after exercise
7,048
$11.68
$82.32K
KANE MATTHEW R.
26 Jan 2021
President and CEO
Sold after exercise
9,697
$13.37
$129.65K
KANE MATTHEW R.
25 Jan 2021
President and CEO
Sold after exercise
9,695
$13.74
$133.21K
KANE MATTHEW R.
22 Jan 2021
President and CEO
Sold after exercise
10,218
$13.53
$138.25K

What was left out

Form 4 filings counted 235
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 27
Sales straight out of an exercise 38
Sales at will 15
Transactions with no price 0
Shares from compensation/vesting 11,715,028
Sales filed before the plan box existed 8
History held since 29 Mar 2019